

Lisa Salvatore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031068/publications.pdf>

Version: 2024-02-01

94
papers

4,499
citations

147801

31
h-index

102487

66
g-index

96
all docs

96
docs citations

96
times ranked

5875
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	27.0	845
2	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 715-721.	6.4	509
3	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852.	10.7	234
4	High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. <i>Oncologist</i> , 2008, 13, 1270-1275.	3.7	218
5	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30.	6.3	160
6	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015, 26, 1188-1194.	1.2	153
7	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	27.6	138
8	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730.	1.2	136
9	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	5.1	126
10	Genetic modulation of the Let-7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab+irinotecan. <i>Pharmacogenomics Journal</i> , 2010, 10, 458-464.	2.0	109
11	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012, 23, 2072-2077.	1.2	108
12	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With KRAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	3.7	94
13	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for KRAS and BRAF Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	7.1	87
14	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013, 24, 2062-2067.	1.2	86
15	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269.	6.4	85
16	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. <i>Annals of Oncology</i> , 2012, 23, 135-141.	1.2	79
17	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 247.	2.6	69
18	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	2.5	64

#	ARTICLE	IF	CITATIONS
19	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	6.4	56
20	PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. <i>Cancers</i> , 2019, 11, 1765.	3.7	54
21	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	2.6	53
22	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine- ⁶ -DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	1.6	52
23	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013, 108, 2549-2556.	6.4	51
24	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ⁶ BRAF BeCool ⁶ ™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
25	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 58.	8.6	46
26	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. <i>Oncotarget</i> , 2015, 6, 33982-33992.	1.8	46
27	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020, 19, 219-225.	2.3	45
28	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	1.2	40
29	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010, 21, 1565.	1.2	38
30	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	4.5	36
31	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1523-1532.	4.1	34
32	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251.	4.4	31
33	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	6.4	29
34	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	2.6	28
35	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 772-779.	2.9	28
36	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	3.6	27

#	ARTICLE	IF	CITATIONS
37	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	3.3	25
38	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	2.8	25
39	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	6.4	24
40	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206.	2.8	22
41	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 315-320.	1.1	21
42	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	4.5	20
43	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.3	20
44	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
45	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. <i>Clinical Colorectal Cancer</i> , 2012, 11, 71-76.	2.3	17
46	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	2.6	17
47	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-657.	1.6	17
48	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6386.	4.1	15
49	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	7.7	14
50	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	2.8	14
51	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	1.6	12
52	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	2.4	12
53	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	2.3	12
54	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845.	3.0	12

#	ARTICLE	IF	CITATIONS
55	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014, 14, 322-327.	2.0	11
56	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001.	4.5	11
57	Management of single pulmonary metastases from colorectal cancer: State of the art. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 820-832.	2.0	10
58	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	4.1	8
59	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
60	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. <i>Cancers</i> , 2021, 13, 2148.	3.7	8
61	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life, Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	8
62	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 167-181.	3.2	7
63	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371.	1.2	7
64	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010, 11, 1247-1256.	1.3	6
65	Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. <i>Cancers</i> , 2021, 13, 574.	3.7	6
66	Refractory neuroendocrine tumor response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 670-674.	27.6	5
67	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 559-566.	2.3	5
68	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. <i>Annals of Oncology</i> , 2013, 24, iv21.	1.2	5
69	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , 2021, 13, 2098.	3.7	5
70	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021, 11, 712053.	2.8	5
71	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3596-3596.	1.6	4
72	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, CRC01.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).. Journal of Clinical Oncology, 2019, 37, 3556-3556.	1.6	3
74	A Novel ATM Pathogenic Variant in an Italian Woman with Gallbladder Cancer. Genes, 2021, 12, 313.	2.4	2
75	Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 2022, 63, 549-555.	5.0	2
76	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664.	1.6	2
77	Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology, 2013, 24, iv15.	1.2	1
78	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	3.0	1
79	Conversion therapy with encorafenib and cetuximab for chemo-refractory BRAF V600E- mutated liver-limited colorectal cancer metastasis: the first case report.. Clinical Colorectal Cancer, 2021, , .	2.3	1
80	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. Journal of Clinical Oncology, 2019, 37, 3550-3550.	1.6	1
81	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Supportive Care in Cancer, 2021, 30, 2455.	2.2	1
82	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	0.5	0
83	P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV). Annals of Oncology, 2012, 23, iv105-iv106.	1.2	0
84	P-0263 Prospective Study of Egfr Intron 1 CA Tandem Repeats as Predictive Factor of Benefit from Cetuximab and Irinotecan. Annals of Oncology, 2012, 23, iv106.	1.2	0
85	Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. Annals of Oncology, 2013, 24, iv28.	1.2	0
86	Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer. JAMA Oncology, 2018, 4, 1297.	7.1	0
87	Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study). Annals of Oncology, 2019, 30, iv87.	1.2	0
88	Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. Annals of Oncology, 2019, 30, iv116.	1.2	0
89	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
90	Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).. Journal of Clinical Oncology, 2019, 37, 3554-3554.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?. Journal of Clinical Oncology, 2019, 37, e15039-e15039.	1.6	0
92	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. Journal of Clinical Oncology, 2019, 37, 3540-3540.	1.6	0
93	Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.. Journal of Clinical Oncology, 2019, 37, 3558-3558.	1.6	0
94	Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.. Journal of Clinical Oncology, 2019, 37, e15038-e15038.	1.6	0